Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.
Crinetics (CRNX) Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback